U.S. FDA Authorizes Pfizer COVID-19 Booster Shots for Older, At-Risk Americans

The United States Food and Drug Administration (FDA) has authorized on Sept. 22 the emergency use of the Pfizer COVID-19 booster dose for older and at-risk people.

The FDA has allowed a single Pfizer COVID-19 booster dose for those aged 65 years and older, those at high risk of severe COVID-19, and those at high risk of COVID-19 exposure at work such as healthcare workers, grocery workers, and teachers.

The booster dose should be administered at least six months after the primary two-dose series, FDA said.

“As we learn more about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed,” Acting FDA Commissioner Janet Woodcock said in a statement.

Vaccine advisers to the Centers for Disease Control and Prevention (CDC) will meet on Sept. 23 to act on the decision of FDA.

The CDC must give its approval for any booster dose to be officially used.

The FDA had already approved a third dose for certain immunocompromised people last month.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.